0 CHECKOUT

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015

  • ID: 3293074
  • May 2015
  • 169 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AB Science
  • ArQule, Inc.
  • Boston Biomedical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mebiopharm Co., Ltd.
  • Merck KGaA
  • MORE

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015

Summary

This, ‘Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015’, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science
  • ArQule, Inc.
  • Boston Biomedical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mebiopharm Co., Ltd.
  • Merck KGaA
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Adenocarcinoma Of The Gastroesophageal Junction Overview
Therapeutics Development
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies
Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development
AB Science
Amgen Inc.
Apceth GmbH & Co. KG
ArQule, Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Gilead Sciences, Inc.
Mebiopharm Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
Panacea Biotec Limited
Sanofi
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Agenmestencel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-337 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-4547 - Drug Profile
AZD-4547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-853520 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-833923 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
catumaxomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRLX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-5745 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMAB-362 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indusatumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBP-426 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solitomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tivantinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab emtansine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenocarcinoma Of The Gastroesophageal Junction - Recent Pipeline Updates
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products
Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones
Featured News & Press Releases
May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting
Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer
Jan 23, 2014: apceth’s Ground-Breaking First-In-Man, First-In-Class Clinical Trial in Oncology with Genetically Modified Mesenchymal Stromal Cells Is Now Enrolling
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2015
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Apceth GmbH & Co. KG, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca PLC, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune, LLC, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H1 2015
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2015
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AB Science
Amgen Inc.
Apceth GmbH & Co. KG
ArQule, Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Gilead Sciences, Inc.
Mebiopharm Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
Panacea Biotec Limited
Sanofi

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)